Jan 19 (Reuters) - Merck & Co Inc:
* FIRST-TIME DATA FOR MERCK‘S KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TO BE PRESENTED AT 2018 ASCO GI SYMPOSIUM
* MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES
* MERCK & CO INC - SEVEN PATIENTS DISCONTINUED TREATMENT DUE TO TREATMENT-RELATED ADVERSE EVENTS
* MERCK & CO INC - THERE WAS ONE TREATMENT-RELATED DEATH IN THE STUDY Source text for Eikon: Further company coverage:
 